The mutation profile of pDC-AML is distinct from BPDCN cases which showed infrequent to absent mutations of RUNX1,  DNMT3A,  BCOR and FLT3, but mutations of TET2 in over half of cases. This evidence concerns the gene FLT3 and acute myeloid leukemia.